Yulia Vugmeyster
Merck KGaA, Darmstadt (Germany)
ORCID: 0000-0002-6289-2521Also affiliated with Merck Serono S.p.A. (Italy)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma”.
Jean‐Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K. Pachynski +14 more
Houssein Abdul Sater, Osama E. Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L. Marté +13 more
Milind M. Javle, Helena Verdaguer Mata, Filippo de Braud, Jörg Trojan, Jean-Luc Raoul +15 more